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Abstract
Next generation sequencing panels are being used increasingly in cancer research
to study tumor evolution. A specific statistical challenge is to compare the mu-
tational profiles in different tumors from a patient to determine the strength of
evidence that the tumors are clonally related, i.e. derived from a single, founder
clonal cell. The presence of identical mutations in each tumor provides evidence
of clonal relatedness, although the strength of evidence from a match is related to
how commonly the mutation is seen in the tumor type under investigation. This
evidence must be weighed against the evidence in favor of independent tumors
from non-matching mutations. In this article we frame this challenge in the con-
text of diagnosis using a novel random effects model. In this way, by analyzing a
set of tumor pairs, we can estimate the proportion of cases that are clonally related
in the sample as well as the individual diagnostic probabilities for each case. The
method is illustrated using data from a study to determine the clonal relationship
of lobular carcinoma in situ with subsequent invasive breast cancers where each
tumor in the pair was subjected to whole exome sequencing. The statistical prop-
erties of the method are evaluated using simulations, demonstrating that the key
model parameters are estimated with only modest bias in small samples.
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Abstract 
Next generation sequencing panels are being used increasingly in cancer research to study 
tumor evolution. A specific statistical challenge is to compare the mutational profiles in 
different tumors from a patient to determine the strength of evidence that the tumors are 
clonally related, i.e. derived from a single, founder clonal cell. The presence of identical 
mutations in each tumor provides evidence of clonal relatedness, although the strength of 
evidence from a match is related to how commonly the mutation is seen in the tumor type 
under investigation. This evidence must be weighed against the evidence in favor of 
independent tumors from non-matching mutations. In this article we frame this challenge in 
the context of diagnosis using a novel random effects model. In this way, by analyzing a set of 
tumor pairs, we can estimate the proportion of cases that are clonally related in the sample as 
well as the individual diagnostic probabilities for each case. The method is illustrated using data 
from a study to determine the clonal relationship of lobular carcinoma in situ with subsequent 
invasive breast cancers where each tumor in the pair was subjected to whole exome 
sequencing. The statistical properties of the method are evaluated using simulations, 
demonstrating that the key model parameters are estimated with only modest bias in small 
samples.  
 
Key Words: clonal relatedness; conditional likelihood; diagnostic probability; mutational testing; 
random effects. 
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1. Introduction 
In recent years there have been increasing numbers of studies evaluating the clonal relatedness 
of distinct tumors in the same patient to determine whether the tumors arise from a common 
ancestral cell or if they developed entirely independently. Examples include studies that 
compared patterns of losses of heterozygosity (e.g. Imyanitov et al. 2002) and studies involving 
comparisons of genome-wide copy number arrays (e.g. Bollet et al. 2008).  Clonality testing of 
this nature seeks to determine if the tumors share somatic mutations or copy number changes, 
providing evidence that the tumors arose from the same precursor, clonal cell. The technology 
for conducting these investigations has changed as genetic technology has evolved, from 
studies of a few markers of loss of heterogeneity to genome-wide studies of copy number 
profiling to, more recently, comparisons of mutational profiles from next generation 
sequencing. Based on such data, the determination of clonal relatedness is fundamentally 
statistical since many of the somatic changes in the tumors may have occurred after the tumors 
have evolved separately, so that the somatic fingerprints of the tumors may be quite different 
even if the tumors are truly clonal. Our group has developed statistical tests for clonal 
relatedness for use in various settings, including studies comparing patterns of losses of 
heterozygosity and genome-wide copy number changes (Begg et al. 2007; Ostrovnaya et al. 
2010a,b).     
Ostrovnaya et al. (2015) recently proposed a statistical test for clonal relatedness based 
on a comparison of the patterns of mutations observed in the two tumors from a sequencing 
panel. A likelihood ratio test was constructed, conditioned on the observed mutations in the 
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two tumors being compared, taking into account the distinct, and widely varying marginal 
probabilities of the specific mutations. These marginal probabilities are important since a 
shared mutation that is very rare, i.e. where the marginal probability of the mutation is very 
small, provides much stronger evidence that the tumors are related than a shared mutation at a 
common locus, where independent occurrence of the same mutation in the tumors is more 
likely. The test was constructed as a classical significance test, where the null hypothesis is that 
the tumors are independent. An important practical characteristic of the test is that it can be 
applied to stand-alone cases, without the need for a larger sample of cases, as long as we have 
information on the marginal probability of occurrence of each specific observed mutation. 
However, an important drawback of using significance testing in this way is that, while the test 
can provide strong evidence against the null, i.e. in favor of clonal relatedness, it does not 
capture the strength of evidence in favor of the null hypothesis, i.e. the hypothesis that the 
tumors are independent. In particular, if no shared mutations are observed, there is no 
evidence for clonality. This is an important issue, since absence of detected matches does not 
define independent tumors. Clonal tumors must possess some matching somatic events, but 
the sequencing panel may simply not cover the genes in which the matches have occurred. 
Logic suggests that the more non-matching events observed the stronger the evidence that the 
tumors are independent, yet the p-value of the test is always 1 when no matches are observed, 
regardless of how many non-shared mutations are observed. The goal of this article is to 
propose a model quantifying the evidence of clonal relatedness for every case, with or without 
observed shared mutations. We use the entire sample of cases to estimate population 
parameters that permit us to assess the strength of evidence for and against clonal relatedness 
http://biostats.bepress.com/mskccbiostat/paper33
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for each individual case. The proposed approach involves using a random effects model to 
capture the variation in the mutational profiles in pairs of clonally related tumors, and using 
this information to estimate the probabilities of clonality for each individual case. The statistical 
properties of the method are examined using simulations.   
The method is illustrated using a recently published study that examined the clonal 
relatedness of pre-malignant lobular carcinoma in situ (LCIS) with subsequent invasive breast 
cancers (Begg et al. 2016). The tumors in the study were profiled using exome sequencing. We 
emphasize that although exome sequencing searches for somatic mutations in the coding 
regions of all genes, matching mutations could exist in the non-coding regions of the genome, 
or could be gains or losses of segments of an allele, i.e. copy number changes. Consequently, 
absence of shared mutations in the exome does not guarantee that the tumors are 
independent. Our analysis is focused on the estimation of the overall proportion of cases that 
are truly clonal, and the diagnostic probabilities of each individual case. 
2. Methods 
2.1 Basic Formulation and Notation 
We consider a sample consisting of n cases (j = 1, … , n) with each case having two 
anatomically distinct tumors. There are G potential genetic loci at which somatic mutations can 
occur. We note that typically G will be a very large number. It is difficult to define it precisely 
since more than one type of substitution can occur at each nucleotide and since there is an 
innumerable number of potential insertions and deletions. However, essentially all of the 
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information regarding the classification of the case as clonal versus independent is contained in 
the somatic mutations that are actually observed to occur (Ostrovnaya et al. 2015). 
Consequently we can adopt an analysis that is conditioned on observed mutations and as a 
result precise definition of G is unnecessary. We therefore define �𝐺𝑗� as the set of mutations 
observed in either or both of the two tumors of the jth case. The marginal probabilities of these 
individual mutations are influential, as the probability of the same mutation being observed in 
two independent tumors decreases as the marginal probability decreases. We define {𝑝𝑖} to be 
the known marginal probabilities of the mutations in the dataset, where 𝑖 indexes the specific 
mutation. 
For each case the observed mutations can be classified as either shared or private. A 
shared mutation is one that is present in both tumors while a private mutation is one that has 
been observed in only one of the tumors. Let 𝐴𝑗 denote the set of observed mutations in the j
th 
case that are shared and let  𝐵𝑗 be the set of private mutations. Thus 𝐺𝑗 = 𝐴𝑗 ∪ 𝐵𝑗.  
The proposed method relies on a case-specific parameter, the clonality signal 𝜉𝑗. This 
represents, in the context of the evolution of the tumors, the relative duration of the period in 
which the original clonal cell accumulated mutations, prior to the period where the two tumors 
evolved separately and accrued additional independent mutations (see Figure 1). Thus 𝜉𝑗 
represents the probability that an observed mutation occurred during the clonal phase as 
opposed to the independent phase of tumor development. For independent tumors, 𝜉𝑗 = 0. It 
follows that for a case with a given clonality signal the probabilities of observing shared and 
private mutations at each locus are given by:- 
http://biostats.bepress.com/mskccbiostat/paper33
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�
𝑃�𝑖 ∈ 𝐴𝑗� 𝜉𝑗� =  𝜉𝑗𝑝𝑖 + �1 −   𝜉𝑗�𝑝𝑖2               
𝑃�𝑖 ∈ 𝐵𝑗� 𝜉𝑗� = 2�1 − 𝜉𝑗�𝑝𝑖(1 − 𝑝𝑖)              
𝑃�𝑖 ∈ 𝐺𝑗� 𝜉𝑗� =  𝜉𝑗𝑝𝑖 +  �1 −   𝜉𝑗�𝑝𝑖(2 − 𝑝𝑖)    (1) 
We further define 𝜋 to be the proportion of clonal cases in the population, i.e. the 
proportion of cases for which 𝜉𝑗 > 0. Finally, we denote by 𝐶𝑗 the event {case 𝑗 is clonal} and by 
𝐶?̅? the event {case 𝑗 is not clonal}. The primary goals of our analysis are to estimate 𝜋, and to 
determine the individual probabilities that the tumor pairs in each case are clonally related 
tumors.  
2.2 Parameter Estimation 
Let 𝑌𝑗 = (𝐴𝑗 ,𝐵𝑗) denote the data from the jth case. We use a likelihood conditional on the 
observed mutations. Let 𝐿𝑗(𝜋,  𝜉𝑗) be the contribution to the conditional likelihood of an 
individual case, defined by: 
𝐿𝑗(𝜋,  𝜉𝑗) = 𝜋𝑃�𝑌𝑗� 𝜉𝑗 ,𝐶𝑗� +  (1 − 𝜋)𝑃�𝑌𝑗�𝐶?̅?� 
where  
𝑃�𝑌𝑗�𝜉𝑗 ,𝐶𝑗� = ∏ �  𝜉𝑗+ (1− 𝜉𝑗)𝑝𝑖 𝜉𝑗+ (1− 𝜉𝑗)(2−𝑝𝑖)�𝐼[𝑖 ∈𝐴𝑗] � 2 (1− 𝜉𝑗)(1−𝑝𝑖) 𝜉𝑗+ (1− 𝜉𝑗)(2−𝑝𝑖)�𝐼[𝑖 ∈𝐵𝑗]𝑖∈𝐺𝑗              
and 
𝑃�𝑌𝑗|𝐶?̅?� =  �� 𝑝𝑖2 − 𝑝𝑖�𝐼[𝑖 ∈𝐴𝑗] �2 (1 − 𝑝𝑖)(2 − 𝑝𝑖) �𝐼[𝑖 ∈𝐵𝑗]
𝑖∈𝐺𝑗
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The marginal likelihood for the entire sample is obtained by integrating the individual 
contributions over the distribution of the random effects as follows: 
𝐿(𝜋, 𝜇,𝜎) =  ∏ ∫ 𝐿𝑗�𝜋,  𝜉𝑗�g�𝜉𝑗�10 𝑑𝜉𝑗𝑛𝑗=1                                              (2) 
where g�𝜉𝑗� denotes the probability density of the random effect 𝜉𝑗. We assume that 𝜉𝑗 = 0 
with probability 1 − 𝜋 and that 𝜙𝑗 = −log (1 − 𝜉𝑗)  follows a 𝑙𝑜𝑔𝑁(𝜇,𝜎2) distribution with 
probability 𝜋. The corresponding density of the clonality signal among clonal cases thus 
depends on 𝜇 and 𝜎, corresponding to the mean and variance of 𝜙𝑗 on the log scale. The model 
parameters 𝜋, 𝜇 and 𝜎 are estimated by maximizing the likelihood 𝐿(𝜋, 𝜇,𝜎). The integral in (2) 
is approximated using adaptive quadrature. The function is maximized using a Newton-like 
method (Byrd et al. 1995). 
Finally, using the parameter estimates and the data from each individual case, we can 
obtain the diagnostic probability that the tumors of a given case are clonally related, i.e.  
𝑃(𝐶𝑗|𝑌𝑗). This probability can be estimated using Bayes formula: 
𝑃�𝐶𝑗�𝑌𝑗� = 𝜋� ∫ 𝑃�𝑌𝑗�𝜉𝑗,𝐶𝑗�g�𝜉𝑗�10 𝑑𝜉𝑗𝜋� ∫ 𝑃�𝑌𝑗�𝜉𝑗,𝐶𝑗�g�𝜉𝑗�10 𝑑𝜉𝑗+ (1−𝜋�)𝑃(𝑌𝑗|𝐶?̅?)                                           (3) 
The R code for the function fitting the model, as well as the example presented in the 
application, is available as Supplementary Materials. 
http://biostats.bepress.com/mskccbiostat/paper33
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3. Application: evaluation of LCIS as a precursor of invasive breast 
cancer 
We illustrate the method using data from a recently published study that was designed to 
investigate the hypothesis that LCIS is a frequent precursor of invasive breast cancer, as 
opposed to merely a marker of increased risk, the prevailing hypothesis for the past 40 years 
(Begg et al. 2016). The study included cases with LCIS lesions, some of which also had ipsilateral 
invasive breast cancers. We focus on the 22 examples of invasive breast cancers for which 
exome sequencing data were available for both the invasive lesion and an index LCIS lesion. The 
median number of mutations per tumor was 33 (range, 15 to 56). 
The results are summarized in Table 1. Columns 2-4 display the numbers of mutations 
observed in each tumor and the numbers of these that were shared. Details of the individual 
mutations observed and their marginal probabilities of occurrence are supplied in 
Supplementary Table 1 of Begg et al. (2016). The marginal probabilities were estimated based 
on their observed relative frequencies in breast cancers in the Cancer Genome Atlas (Cancer 
Genome Atlas Network 2012) combined with our current study.  Among the 22 studied pairs, 
14 pairs (64%) had evidence favoring clonality from the whole-exome sequencing (identified by 
an asterisk in Table 1). These cases had at least one shared mutation. Using the methods from 
Section 2 the proportion of clonal cases in the population was estimated at 75%. The 
parameters of the normal distribution were estimated to be ?̂? = −2.26 and 𝜎� = 1.47, 
representing a density function that is positively skewed, i.e. for the preponderance of clonal 
cases the clonality signal is considerably less than 0.5. In cases with at least one observed 
Hosted by The Berkeley Electronic Press
10 
 
shared mutation, the estimated probabilities of clonal relatedness ranged from 0.87 to >0.99. 
The probabilities of clonal relatedness in cases with no observed shared mutations range from 
0.31 to 0.38.  
We also analyzed the data using the previously proposed clonality test (Ostrovnaya et al. 
2015). These p-values are in the final column of Table 1. We see that all cases with at least one 
match are significant at the 5% level. In this sense the two methods are consistent, classifying 
these patients as clonal. However, the p-value is always 1 when no matches are observed, while 
the random effects model provides individual probability estimates in these cases. 
In this example, all pairs with a single shared mutation have a high probability of being 
clonal (>85%). The reason is that the shared mutation is a rare mutation, i.e. a mutation with an 
estimated marginal probability of occurrence of 0.001 (pairs 47c, 48b, 53b) and 0.003 (pair 
47d). To illustrate the influence of this marginal probability we have recalculated the probability 
of clonal relatedness for case 47c by replacing the marginal probability of the shared mutation 
with the values 0.01 and 0.1, representing the frequencies of more commonly occurring 
mutations. In these circumstances the probability of clonality would be reduced from 94% to 
68% and 42%, respectively.  
Similarly, we can assess the sensitivity of the probability to the total number of 
mutations when no shared mutations are observed. Let’s consider case 26, with 32 and 29 
observed mutations in the two tumors (61 total), but none shared. In this case the probability 
of clonality is 35%. This probability would be 26% if 100 mutations were observed. By contrast, 
http://biostats.bepress.com/mskccbiostat/paper33
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the probability would be 61% if only 10 mutations were observed, and it becomes closer to the 
estimated 𝜋�  as the number decreases. 
Finally, we acknowledge that each of the 22 cases analyzed involves a unique invasive 
lesion but in fact some tumor pairs actually come from the same case (indicated by the case 
numbers). For example in case #24 there were two distinct LCIS lesions, and we tested these 
separately for clonal relatedness with the same invasive lesion. The model is based on the 
implicit assumption that these pairs are independent. 
4. Statistical Properties  
Our data analysis in Section 3 was based on a relatively small sample size with a modest 
proportion of cases determined to be clonal. Further, since the model parameters, especially 
those defining the random effects distribution of clonality signals, are derived primarily from 
the subset of cases that are clonal, evaluation of the statistical properties of the method is 
essential, especially for datasets with small sample sizes.  
Analyses of this type will inevitably involve large numbers of genetic loci, most of which 
will have a very small probability of experiencing a mutation in any given tumor, and a much 
smaller number of hot spot mutations with relatively large mutation probabilities. We 
simulated data using the framework of the breast cancer data in Section 3 to construct the 
distribution of marginal mutation probabilities. These probabilities of mutation 𝑝𝑖, 𝑖 = 1, … ,𝐺, 
were sampled with replacement from the set of observed mutations in the breast cancer study. 
We set 𝐺 = 19000 mutational loci, representing in theory the set of distinct mutations that 
Hosted by The Berkeley Electronic Press
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could occur. In reality there are billions of loci in the exome that could experience a mutation. 
The use of G = 19000 was chosen to produce a mean of 34 mutations per case, similar to the 
mean observed in our LCIS study. We varied the true values of the parameters, 𝜋, 𝜇 and 𝜎, and 
the sample size n. Each of 200 simulation runs was then generated as follows. For each case, we 
determined randomly with probability 𝜋 whether or not the case was clonal. For each clonal 
case, we simulated its clonality signal 𝜉𝑗 =1-exp(-𝜙𝑗), where 𝜙𝑗   is sampled from a log-normal 
distribution with parameters (𝜇,𝜎). Figure 2 displays the selected distributional scenarios used 
in our simulations. These scenarios were chosen to reflect settings where the typical signals 
produce few matches (scenarios 1 and 2), where the typical signals lead to mutations being 
predominantly matches (scenarios 4 and 5), and one scenario (3) where there is typically a 
more even distribution of matches and non-matches. For each distinct potential mutation 𝑖, we 
determined if a clonal or a private or no mutation was observed by sampling from trinomial 
probabilities (𝑝𝐴,𝑝𝐵, 1 − 𝑝𝐴 − 𝑝𝐵), where 𝑝𝐴 = 𝑃�𝑖 ∈ 𝐴𝑗  | 𝜉𝑗� and 𝑝𝐵 = 𝑃�𝑖 ∈ 𝐵𝑗 | 𝜉𝑗� as 
defined in (1). If the case involved independent tumors then the trinomial sampling 
probabilities were replaced with 𝑝𝐴 = 𝑃�𝑖 ∈ 𝐴𝑗  | 𝜉𝑗 = 0� and 𝑝𝐵 = 𝑃�𝑖 ∈ 𝐵𝑗  | 𝜉𝑗 = 0�. The 
resulting dataset was then analyzed using the method from Section 2 and the results 
summarized as described below. 
In Table 2 we display results for three sample size settings: n=25, representing the 
approximate size of our breast cancer example, n=100 and n=1000. For each configuration, 
biases of the parameter estimates were calculated by subtracting the true parameter value 
from the mean of the parameter estimates from the 1000 simulations. We see that the clonal 
prevalence parameter π is estimated with essentially no bias in large sample sizes and very 
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modest bias in small sample sizes, except for the extreme scenario 1 where somewhat larger 
biases are observed. The high number of small values for the signal 𝜉𝑗 in this scenario makes it 
difficult for the model to distinguish between clonal cases with low signals and non-clonal cases 
with a null signal. The parameters of the random effects distribution of the clonality signals, 𝜇 
and 𝜎, are estimated with nearly no bias for large sample sizes, and with modest biases for 
medium and small sample sizes. These parameters are, however, not of intrinsic importance. 
What is important is their effect on the estimates of the predicted probabilities of clonal 
relatedness for each individual case.  
The predicted probabilities are estimated using (3) while true probabilities were 
calculated using (3) with 𝜋 and the true parameters for the distribution of 𝜉𝑗  replacing the 
corresponding estimates. The prediction error is defined as the mean absolute difference 
between the two measures. Prediction errors computed during the simulations, using 100 new 
cases that were not involved in the model estimation, are relatively small for small sample size 
and almost null for large sample sizes, except for scenario 1 where it can reach 14% when n=25.  
We also studied alternative models for the random effects distribution, notably the beta 
model. However, although π was estimated typically with modest bias the estimates for the 
distribution parameters α and β were heavily biased (data not shown). To assess the robustness 
of the lognormal model to model misspecification we simulated data according to a Beta 
distribution and estimated the model assuming the lognormal distribution. Results are 
displayed in Table 3. The biases are substantially higher than when the models are aligned as in 
Table 1. However the biases are generally modest for π except when π is very large, and the 
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prediction errors are modest, demonstrating that model mis-specification has limited adverse 
consequences on the key parameter estimates.     
5. Discussion 
In this work we aimed at assessing clonal relatedness based on comparisons of somatic 
mutational profiles of two tumors. We have framed the problem as one of differential 
diagnosis, rather than significance testing. The proposed method estimates three quantities of 
importance: the proportion of clonal cases in the population of interest, the distribution of the 
clonality signal, and individual probabilities of clonality for each case. This addresses the 
problem that the significance testing approach does not provide quantitative evidence in favor 
of the (null) hypothesis that the tumors are independent, regardless of the numbers of non-
matching mutations observed (Ostrovnaya et al. 2015). We resolved this problem by modeling 
the data from the entire sample of cases using a random effects model with a marginal 
likelihood, estimating the proportion of cases that are clonal, and reframing the problem as one 
of diagnosis. In our illustrative example based on a relatively small sample of cases with LCIS 
paired with an invasive breast cancer in which exome sequencing was performed on all of the 
tumors we were able to successfully obtain estimates of all of the relevant probabilities. Our 
simulations demonstrate that the method has good properties even for relatively small sample 
sizes as in the example.  
Our study of LCIS and invasive cancers addressed a theoretical question of interest to 
breast cancer specialists: is LCIS a precursor of invasive cancer or merely a marker of elevated 
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risk? Clonality studies are clearly useful for addressing specific scientific questions of this 
nature. Moreover these methods are likely to have much broader clinical applicability as 
sequencing of tumors becomes more common practice in the clinic. Although formal testing for 
clonal relatedness is not yet commonly used in clinical practice, its potential value is clear. For 
example, in breast cancer it has been found that the patient’s survival probability is lower for 
patients with a locoregional recurrence compared to patients with a second primary cancer, 
emphasizing the importance of distinguishing local recurrences from ipsilateral second 
primaries (Witteveen et al. 2015). In this and numerous other clinical settings, determining 
whether two tumors are clonally related can have important clinical implications, since the 
presence of distinct, clonally related tumors represents metastasis and the consequent need 
for systemic therapy, while two independent tumors might both be effectively treated by local 
therapy, such as surgery, depending on the clinical context (Klevebring et al. 2015). Recent 
publications have demonstrated that pathologists’ judgment can frequently be wrong, notably 
when diagnosing multiple lung tumors (Girard et al. 2009; Wang et al. 2009). Increasingly, 
cancer hospitals are introducing genetic tests to sequence tumors as a routine clinical tool 
(Wagle et al. 2012). The primary goal is to identify “actionable” mutations that could serve as 
targets for drugs specially designed to act against the identified mutations. The routine 
availability of information on mutations in such gene panels will inevitably provide data that 
can potentially be used for clonality testing when a new tumor is identified in the patient and 
there is doubt as to whether this represents an independent primary cancer or a recurrence of 
the initial tumor. However, gene panels for clinical use typically contain far fewer genes than 
the whole exome panel used in our study. As a result the numbers of observed mutations will 
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necessarily be much smaller, and it is intuitive that there is a greater chance that shared 
mutations will not be observed in tumor pairs that are truly clonal. Consequently, it will be 
necessary to examine more carefully the properties of the method in the setting where 
candidate gene panels are employed.   
Our proposed method makes a number of assumptions. First, we assume that the 
marginal mutation probabilities are known, when in fact they are estimated. Second, we 
assume that the order in which mutations occur is random, when in fact it is plausible that 
common mutations are more likely to occur earlier in tumor evolution. Third, uncertainty exists 
with respect to the accuracy of mutation calling. Further research is needed to explore the 
impact of these assumptions on the properties of the method. Our approach is conceptually 
similar to other mixture models that have been developed to account for an excess of zeros in 
count data, notably using Poisson regression (see for example Lam et al. 2006, Ma et al. 2009, 
and Wong and Lam 2013 for application in medical studies), although the model structure and 
estimation strategies we have used are novel in this context.  
In summary, we have developed a practical statistical modeling approach to a complex 
problem involving the use of genomic data to diagnose tumor pairs as related (clonal) or 
independent. Our method involves a novel application of well known statistical strategies, 
including random effects modeling and zero inflated distributions, applied to sparse data. Our 
simulations demonstrate that the method has good statistical properties in relatively large 
samples. In the small sample setting, although the parameters of the random effects 
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distribution are estimated with bias, the method succeeds in estimating the key diagnostic 
parameters with only modest bias. 
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Table 1: Data and Diagnostic Probabilities 
Pair LCIS Invasive Shared Probability Pair is Clonal 
P-Value from the 
Hypothesis Test 
24a* 36 34 25 >0.99 <10-4 
24b* 29 34 2 >0.99 4. 10-4 
26 29 32 0 0.35 1 
46a 46 15 0 0.35 1 
46b 37 15 0 0.38 1 
47a* 29 25 7 >0.99 <10-4 
47b* 22 25 7 >0.99 <10-4 
47c* 29 30 1 0.94 0.02 
47d* 22 30 1 0.87 0.03 
48a* 33 40 20 >0.99 <10-4 
48b* 22 40 1 0.94 0.03 
53a* 21 23 2 >0.99 2. 10-4 
53b* 17 23 1 0.97 0.02 
55* 31 36 6 >0.99 <10-4 
68 44 33 0 0.31 1 
69* 56 31 18 >0.99 <10-4 
73 26 42 0 0.33 1 
74a 34 34 0 0.33 1 
74b 37 34 0 0.32 1 
74c* 43 34 3 >0.99 <10-4 
75a* 46 39 15 >0.99 <10-4 
75b 22 29 0 0.38 1 
Model parameter estimates: ?̂? = −2.26,𝜎� = 1.47,𝜋� = 0.75. 
*Asterisks identify patients with evidence favoring clonality.  
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Table 2: Simulation results - lognormal distribution 
Scenario 
 π   𝜇  σ Prediction 
Error  Estimate (sd) Bias  Estimate Bias  Estimate Bias 
N=25 cases           
𝜋 (𝜇 ; σ)           
0.10 Sc 1: (-2.0 ; 1.5) 0.139 (0.218) 0.039   -1.62 0.38   1.06 -0.44 0.103 
 Sc 2: (-1 ; 1) 0.122 (0.139) 0.022   -1.08 -0.08   0.74 -0.26 0.046 
 Sc 3: (-0.25 ; 0.50) 0.108 (0.069) 0.008   -0.38 -0.13   0.45 -0.05 0.013 
 Sc 4: (0.55 ; 0.45) 0.104 (0.062) 0.004   0.40 -0.15   0.43 -0.02 0.009 
 Sc 5: (0.7 ; 0.3) 0.104 (0.061) 0.004   0.56 -0.14   0.36 0.06 0.009 
0.25 Sc 1: (-2.0 ; 1.5) 0.273 (0.189) 0.023   -1.91 0.09   1.08 -0.42 0.105 
 Sc 2: (-1 ; 1) 0.262 (0.115) 0.012   -1.10 -0.10   0.82 -0.18 0.035 
 Sc 3: (-0.25 ; 0.50) 0.250 (0.090) 0.000   -0.28 -0.03   0.41 -0.09 0.003 
 Sc 4: (0.55 ; 0.45) 0.249 (0.088) -0.001   0.53 -0.02   0.38 -0.07 0.001 
 Sc 5: (0.7 ; 0.3) 0.249 (0.087) -0.001   0.69 -0.01   0.26 -0.04 0.000 
0.50 Sc 1: (-2.0 ; 1.5) 0.528 (0.211) 0.028   -2.04 -0.04   1.32 -0.18 0.137 
 Sc 2: (-1 ; 1) 0.506 (0.116) 0.006   -1.06 -0.06   0.95 -0.05 0.034 
 Sc 3: (-0.25 ; 0.50) 0.499 (0.100) -0.001   -0.27 -0.02   0.47 -0.03 0.002 
 Sc 4: (0.55 ; 0.45) 0.498 (0.100) -0.002   0.54 -0.01   0.42 -0.03 0.000 
 Sc 5: (0.7 ; 0.3) 0.498 (0.100) -0.002   0.69 -0.01   0.27 -0.03 0.000 
0.75 Sc 1: (-2.0 ; 1.5) 0.747 (0.168) -0.003   -1.97 0.03   1.35 -0.15 0.122 
 Sc 2: (-1 ; 1) 0.759 (0.103) 0.009   -1.04 -0.04   0.96 -0.04 0.037 
 Sc 3: (-0.25 ; 0.50) 0.754 (0.087) 0.004   -0.26 -0.01   0.47 -0.03 0.002 
 Sc 4: (0.55 ; 0.45) 0.754 (0.087) 0.004   0.54 -0.01   0.43 -0.02 0.000 
 Sc 5: (0.7 ; 0.3) 0.754 (0.087) 0.004   0.69 -0.01   0.28 -0.02 0.000 
N=100 cases           
𝜋 (𝜇 ; σ)           
0.10 Sc 1: (-2.0 ; 1.5) 0.121 (0.122) 0.021   -1.98 0.02   1.17 -0.33 0.051 
 Sc 2: (-1 ; 1) 0.105 (0.040) 0.005   -1.10 -0.10   0.90 -0.10 0.013 
 Sc 3: (-0.25 ; 0.50) 0.100 (0.031) 0.000   -0.27 -0.02   0.44 -0.06 0.001 
 Sc 4: (0.55 ; 0.45) 0.100 (0.031) 0.000   0.54 -0.01   0.40 -0.05 0.000 
 Sc 5: (0.7 ; 0.3) 0.100 (0.031) 0.000   0.69 -0.01   0.26 -0.04 0.000 
0.25 Sc 1: (-2.0 ; 1.5) 0.266 (0.101) 0.016   -2.09 -0.09   1.42 -0.08 0.058 
 Sc 2: (-1 ; 1) 0.251 (0.050) 0.001   -1.04 -0.04   0.96 -0.04 0.013 
 Sc 3: (-0.25 ; 0.50) 0.250 (0.043) 0.000   -0.27 -0.02   0.48 -0.02 0.001 
 Sc 4: (0.55 ; 0.45) 0.250 (0.043) 0.000   0.54 -0.01   0.43 -0.02 0.000 
 Sc 5: (0.7 ; 0.3) 0.250 (0.043) 0.000   0.69 -0.01   0.29 -0.01 0.000 
0.50 Sc 1: (-2.0 ; 1.5) 0.508 (0.113) 0.008   -2.05 -0.05   1.47 -0.03 0.069 
 Sc 2: (-1 ; 1) 0.497 (0.054) -0.003   -1.01 -0.01   0.98 -0.02 0.013 
 Sc 3: (-0.25 ; 0.50) 0.498 (0.049) -0.002   -0.26 -0.01   0.49 -0.01 0.001 
 Sc 4: (0.55 ; 0.45) 0.498 (0.049) -0.002   0.54 -0.01   0.45 0.00 0.000 
 Sc 5: (0.7 ; 0.3) 0.499 (0.049) -0.001   0.69 -0.01   0.30 0.00 0.000 
0.75 Sc 1: (-2.0 ; 1.5) 0.764 (0.115) 0.014   -2.07 -0.07   1.48 -0.02 0.081 
 Sc 2: (-1 ; 1) 0.750 (0.051) 0.000   -1.03 -0.03   0.99 -0.01 0.014 
 Sc 3: (-0.25 ; 0.50) 0.750 (0.044) 0.000   -0.27 -0.02   0.50 0.00 0.001 
 Sc 4: (0.55 ; 0.45) 0.751 (0.044) 0.001   0.54 -0.01   0.45 0.00 0.000 
 Sc 5: (0.7 ; 0.3) 0.751 (0.044) 0.001   0.69 -0.01   0.30 0.00 0.000 
N=1000 cases           
𝜋 (𝜇 ; σ)           
0.10 Sc 1: (-2.0 ; 1.5) 0.104 (0.022) 0.004   -2.07 -0.07   1.50 0.00 0.014 
 Sc 2: (-1 ; 1) 0.100 (0.011) 0.000   -1.01 -0.01   0.99 -0.01 0.003 
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 Sc 3: (-0.25 ; 0.50) 0.101 (0.010) 0.001   -0.26 -0.01   0.50 0.00 0.000 
 Sc 4: (0.55 ; 0.45) 0.101 (0.010) 0.001   0.54 -0.01   0.45 0.00 0.000 
 Sc 5: (0.7 ; 0.3) 0.101 (0.010) 0.001   0.69 -0.01   0.30 0.00 0.000 
0.25 Sc 1: (-2.0 ; 1.5) 0.249 (0.028) -0.001   -2.01 -0.01   1.48 -0.02 0.016 
 Sc 2: (-1 ; 1) 0.248 (0.015) -0.002   -1.01 -0.01   0.99 -0.01 0.004 
 Sc 3: (-0.25 ; 0.50) 0.249 (0.014) -0.001   -0.26 -0.01   0.50 0.00 0.000 
 Sc 4: (0.55 ; 0.45) 0.250 (0.014) 0.000   0.54 -0.01   0.45 0.00 0.000 
 Sc 5: (0.7 ; 0.3) 0.250 (0.014) 0.000   0.69 -0.01   0.30 0.00 0.000 
0.50 Sc 1: (-2.0 ; 1.5) 0.496 (0.031) -0.004   -2.00 0.00   1.48 -0.02 0.019 
 Sc 2: (-1 ; 1) 0.498 (0.019) -0.002   -1.01 -0.01   0.99 -0.01 0.004 
 Sc 3: (-0.25 ; 0.50) 0.500 (0.017) 0.000   -0.26 -0.01   0.50 0.00 0.000 
 Sc 4: (0.55 ; 0.45) 0.500 (0.017) 0.000   0.54 -0.01   0.45 0.00 0.000 
 Sc 5: (0.7 ; 0.3) 0.500 (0.017) 0.000   0.69 -0.01   0.30 0.00 0.000 
0.75 Sc 1: (-2.0 ; 1.5) 0.744 (0.033) -0.006   -2.00 0.00   1.48 -0.02 0.023 
 Sc 2: (-1 ; 1) 0.748 (0.016) -0.002   -1.01 -0.01   1.00 0.00 0.005 
 Sc 3: (-0.25 ; 0.50) 0.750 (0.014) 0.000   -0.26 -0.01   0.50 0.00 0.000 
 Sc 4: (0.55 ; 0.45) 0.750 (0.014) 0.000   0.54 -0.01   0.45 0.00 0.000 
 Sc 5: (0.7 ; 0.3) 0.750 (0.014) 0.000   0.69 -0.01   0.30 0.00 0.000 
Data are generated with an average number of mutations per cases ≈34, to correspond to the LCIS study. 
Number of loci = 19,000; 1000 simulations per scenario. 
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Table 3: Simulation results - data simulated according to a Beta distibution, estimation 
assuming a log-normal distribution. 
Scenario 
 π   𝜇  σ Prediction 
Error  Estimate (sd) Bias  Estimate  Estimate 
N=25 cases         
𝜋 (𝜶 ; β)         
0.10 Sc 1: (0.8 ; 0.8) 0.114 (0.114) 0.014   -0.56   0.85 0.041 
 Sc 2: (1 ; 1) 0.116 (0.109) 0.016   -0.57   0.79 0.037 
 Sc 3: (2 ; 2) 0.112 (0.108) 0.012   -0.58   0.63 0.028 
 Sc 4: (0.9 ; 3.0) 0.111 (0.142) 0.011   -1.42   0.87 0.063 
0.25 Sc 1: (0.8 ; 0.8) 0.244 (0.101) -0.006   -0.50   0.96 0.034 
 Sc 2: (1 ; 1) 0.246 (0.097) -0.004   -0.50   0.87 0.027 
 Sc 3: (2 ; 2) 0.254 (0.086) 0.004   -0.47   0.62 0.011 
 Sc 4: (0.9 ; 3.0) 0.259 (0.171) 0.009   -1.64   0.74 0.082 
0.50 Sc 1: (0.8 ; 0.8) 0.474 (0.110) -0.026   -0.44   1.07 0.040 
 Sc 2: (1 ; 1) 0.483 (0.111) -0.017   -0.43   0.97 0.030 
 Sc 3: (2 ; 2) 0.497 (0.103) -0.003   -0.44   0.68 0.012 
 Sc 4: (0.9 ; 3.0) 0.466 (0.147) -0.034   -1.56   0.84 0.082 
0.75 Sc 1: (0.8 ; 0.8) 0.714 (0.101) -0.036   -0.42   1.08 0.046 
 Sc 2: (1 ; 1) 0.727 (0.099) -0.023   -0.43   0.98 0.036 
 Sc 3: (2 ; 2) 0.742 (0.088) -0.008   -0.42   0.70 0.013 
 Sc 4: (0.9 ; 3.0) 0.693 (0.130) -0.057   -1.53   0.88 0.091 
N=100 cases         
𝜋 (𝜶 ; β)         
0.10 Sc 1: (0.8 ; 0.8) 0.096 (0.034) -0.004   -0.40   0.99 0.012 
 Sc 2: (1 ; 1) 0.098 (0.033) -0.002   -0.44   0.91 0.009 
 Sc 3: (2 ; 2) 0.099 (0.032) -0.001   -0.44   0.66 0.004 
 Sc 4: (0.9 ; 3.0) 0.105 (0.094) 0.005   -1.61   0.80 0.033 
0.25 Sc 1: (0.8 ; 0.8) 0.234 (0.046) -0.016   -0.38   1.06 0.019 
 Sc 2: (1 ; 1) 0.240 (0.045) -0.010   -0.41   0.97 0.014 
 Sc 3: (2 ; 2) 0.247 (0.044) -0.003   -0.42   0.70 0.005 
 Sc 4: (0.9 ; 3.0) 0.227 (0.057) -0.023   -1.52   0.88 0.034 
0.50 Sc 1: (0.8 ; 0.8) 0.470 (0.054) -0.030   -0.39   1.10 0.031 
 Sc 2: (1 ; 1) 0.477 (0.053) -0.023   -0.42   0.99 0.022 
 Sc 3: (2 ; 2) 0.493 (0.052) -0.007   -0.42   0.71 0.008 
 Sc 4: (0.9 ; 3.0) 0.450 (0.060) -0.050   -1.51   0.91 0.050 
0.75 Sc 1: (0.8 ; 0.8) 0.707 (0.050) -0.043   -0.39   1.11 0.041 
 Sc 2: (1 ; 1) 0.721 (0.048) -0.029   -0.42   1.01 0.029 
 Sc 3: (2 ; 2) 0.739 (0.044) -0.011   -0.42   0.72 0.009 
 Sc 4: (0.9 ; 3.0) 0.680 (0.062) -0.070   -1.51   0.91 0.069 
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Figure 1: Shema of two tumors from the same clone versus two independent tumors. 
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Figure 2: Different scenarios for the simulations. 
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